炎症性筋疾患（IM） - 市場考察、疫学、市場予測（2032年）

主なハイライト

• 炎症性筋疾患（IM）の市場規模は、2022年に主要7市場の中で米国がもっとも大きく、約2億9,300万米ドルを占め、2032年までにさらに拡大する見込みです。
• 調査期間中（2019年～2032年）に市場に登場すると予想される製品には、Efgartigimod alfa、Ravulizumab、Brepocitinib、PF-06823859、Hizentraなどがあります。

炎症性筋疾患（IM）市場の見通し

炎症性筋疾患（IM）の治療法は年々進化しています。現在の治療アプローチでは、コルチコステロイドや疾患修飾性抗リウマチ薬（DMARD）などの免疫抑制剤、生物学的製剤、理学療法、支持療法などを組み合わせています。しかし、副作用の少ない、より効果的で的を絞った治療に対するニーズはまだ満たされていません。生物学的製剤や低分子阻害剤を含む新しい治療法の開発は、患者に新たな選択肢を提供することで、市場の見通しに大きな影響を与える可能性があります。

• 主要7市場の炎症性筋疾患（IM）の総市場規模は、2022年に約5億7,500万米ドルで、予測期間中（2023年～2032年）に拡大すると予測されます。
• 主要7市場の市場規模は、疾患に対する認識の高まりと新薬の発売により、CAGRで約11.7%の成長が見込まれています。
• EU諸国のうち、2022年の市場規模はドイツが6,800万米ドル、イタリアが4,600万米ドルで最大となり、スペインが2,100万米ドルで最下位です。
• 日本は2022年に7,100万米ドルの市場規模を占めましたが、これらの力学は今後数年で変化すると予測されます。

当レポートでは、炎症性筋疾患（IM）の主要7市場について調査分析し、市場規模と予測、現在の治療法と新薬の情報などを提供しています。

目次

第1章 主要考察

第2章 レポートのイントロダクション

第3章 炎症性筋疾患（IM）市場の概要

• 炎症性筋疾患（IM）の市場シェア分布（2019年）
• 炎症性筋疾患（IM）の市場シェア分布（2032年）

第4章 疫学と市場予測手法

第5章 主な出来事

第6章 炎症性筋疾患（IM）のエグゼクティブサマリー

第7章 疾患の背景と概要：炎症性筋疾患（IM）

• イントロダクション
• 臨床症状
• 病因と危険因子
• 免疫病原性
  • 病因
  • 筋炎における筋肉損傷の自然免疫機構
  • 骨格筋におけるTLRシグナル伝達
• 炎症性筋疾患（IM）に関連する併存疾患
• 診断
  • 鑑別診断
  • 診断ガイドライン
• 管理と治療
  • 治療ガイドライン

第8章 ペイシェントジャーニー

第9章 炎症性筋疾患（IM）の疫学と患者人口

• 主な調査結果
• 前提条件と根拠：主要7市場
  • 米国
  • 欧州4ヶ国・英国
  • 日本
• 主要7市場の炎症性筋疾患（IM）と診断された症例
• 米国
• 欧州4ヶ国・英国
• 日本

第10章 上市済み薬品

• OCTAGAM 10% (intravenous immune globulin [human]): Octapharma

第11章 新しい治療法

• 主な競合
• Hizentra: CSL Behring
• PF 1801: Immunoforge Co. Ltd.
• Efgartigimod: Argenx
• Nipocalimab: Janssen
• ABC008: Abcuro, Inc.
• Daxdilimab (HZN-7734/MEDI7734/VIB7734): Horizon Therapeutics
• Enpatoran (M5049): Merck KGaA
• GLPG3667: Galapagos NV
• Brepocitinib (PF-06700841): Priovant Therapeutics/Roivant
• ULTOMIRIS (Ravulizumab): Alexion Pharmaceuticals
• PF-06823859 (Dazukibart): Pfizer
• Zetomipzomib (KZR-616): Kezar Life Sciences

第12章 炎症性筋疾患（IM）：主要7市場の分析

• 主な調査結果
• 市場見通し
• 主な市場予測の前提条件
• 主要7市場の炎症性筋疾患（IM）の市場規模
• 主要7市場の炎症性筋疾患（IM）の市場規模：治療法別
  • 炎症性筋疾患（IM）の総市場規模
  • 炎症性筋疾患（IM）の市場規模：治療法別
• 欧州4ヶ国・英国の炎症性筋疾患（IM）の市場規模
• 日本の炎症性筋疾患（IM）の市場規模

第13章 主なオピニオンリーダーの見解

第14章 SWOT分析

第15章 アンメットニーズ

第16章 市場参入と償還

• 米国
• 欧州4ヶ国・英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • 英国
• 日本

第17章 付録

第18章 DelveInsightのサービス内容

第19章 免責事項

List of Tables

• Table 1: Key Events
• Table 2: Summary of Inflammatory Myositis Market and Epidemiology (2019-2032)
• Table 3: Diagnosed Prevalent Cases of Inflammatory Myositis in the 7MM (2019-2032)
• Table 4: Diagnosed Prevalent Cases of Inflammatory Myositis in the United States (2019-2032)
• Table 5: Gender-specific Diagnosed Prevalent Cases of Inflammatory Myositis in the United States (2019-2032)
• Table 6: Age-specific Diagnosed Prevalent Cases of Inflammatory Myositis in the United States in '000s (2019-2032)
• Table 7: Diagnosed Prevalent Cases of Inflammatory Myositis in EU4 and the UK (2019-2032)
• Table 8: Gender-specific Diagnosed Prevalent Cases of Inflammatory Myositis in EU4 and the UK (2019-2032)
• Table 9: Age-specific Diagnosed Prevalent Cases of Inflammatory Myositis in EU4 and the UK (2019-2032)
• Table 10: Diagnosed Prevalent Cases of Inflammatory Myositis in Japan (2019-2032)
• Table 11: Gender-specific Diagnosed Prevalent Cases of Inflammatory Myositis in Japan (2019-2032)
• Table 12: Age-specific Diagnosed Prevalent Cases of Inflammatory Myositis in Japan (2019-2032)
• Table 13: Octagam 10%, Clinical Trial Description, 2023
• Table 14: Total Improvement Score - Proportion of Responders by Improvement Category at Week 16
• Table 15: Key Competitors - Emerging drugs
• Table 16: Hizentra, Clinical Trial Description, 2023
• Table 17: PF-1801, Clinical Trial Description, 2023
• Table 18: EFG PH20, Clinical Trial Description, 2023
• Table 19: Nipocalimab, Clinical Trial Description, 2023
• Table 20: ABC008, Clinical Trial Description, 2023
• Table 21: Daxdilimab, Clinical Trial Description, 2023
• Table 22: M5049, Clinical Trial Description, 2023
• Table 23: GLPG3667, Clinical Trial Description, 2023
• Table 24: Brepocitinib, Clinical Trial Description, 2023
• Table 25: Ravulizumab, Clinical Trial Description, 2023
• Table 26: PF-06823859, Clinical Trial Description, 2023
• Table 27: Zetomipzomib (KZR-616), Clinical Trial Description, 2023
• Table 28: Summarized Safety and Tolerability of Zetomipzomib for the 32-week PRESIDIO Trial
• Table 29: Key Market Forecast Assumptions for Efgartigimod
• Table 30: Key Market Forecast Assumptions for Zetomipzomib (KZR-616)
• Table 31: Key Market Forecast Assumptions for Ravulizumab (Ultomiris)
• Table 32: Key Market Forecast Assumptions for Brepocitinib (PF-06700841)
• Table 33: Key Market Forecast Assumptions for PF-06823859
• Table 34: Key Market Forecast Assumptions for Hizentra
• Table 35: Market Size of Inflammatory Myositis in the 7MM, in USD million (2019-2032)
• Table 36: Market Size of Inflammatory Myositis by Therapies in the 7MM, in USD million (2019-2032)
• Table 37: Market Size of Inflammatory Myositis in the United States, in USD million (2019-2032)
• Table 38: Market Size of Inflammatory Myositis by Therapies in the US, in USD million (2019-2032)
• Table 39: Market Size of Inflammatory Myositis in EU4 and the UK, in USD million (2019-2032)
• Table 40: Market Size of Inflammatory Myositis by Therapies in Germany, in USD million (2019-2032)
• Table 41: Market Size of Inflammatory Myositis by Therapies in France, in USD million (2019-2032)
• Table 42: Market Size of Inflammatory Myositis by Therapies in Italy, in USD million (2019-2032)
• Table 43: Market Size of Inflammatory Myositis by Therapies in Spain, in USD million (2019-2032)
• Table 44: Market Size of Inflammatory Myositis by Therapies in the UK, in USD million (2019-2032)
• Table 45: Market Size of Inflammatory Myositis by Therapies in EU4 and the UK, in USD million (2019-2032)
• Table 46: Market Size of Inflammatory Myositis in Japan, in USD million (2019-2032)
• Table 47: Market Size of Inflammatory Myositis by Therapies in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: Classification Progression for IM over the years
• Figure 2: International Diagnostic Criteria for Polymyositis and Dermatomyositis
• Figure 3: Current Treatment Algorithm for Idiopathic Inflammatory Myositis (IM)
• Figure 4: Current Treatment Algorithm for Idiopathic Inflammatory Myositis (IM)
• Figure 5: Recommendations for Dermatomyositis
• Figure 6: Patient Journey of Inflammatory Myositis
• Figure 7: Diagnosed Prevalent cases of Inflammatory Myositis in the 7MM (2019-2032)
• Figure 8: Diagnosed Prevalent Cases of Inflammatory Myositis in the United States (2019-2032)
• Figure 9: Gender-specific Diagnosed Prevalent Cases of Inflammatory Myositis in the United States (2019-2032)
• Figure 10: Age-specific Diagnosed Prevalent Cases of Inflammatory Myositis in the United States in '000s (2019-2032)
• Figure 11: Diagnosed Prevalent Cases of Inflammatory Myositis in EU4 and the UK (2019-2032)
• Figure 12: Gender-specific Diagnosed Prevalent Cases of Inflammatory Myositis in EU4 and the UK (2019-2032)
• Figure 13: Age-specific Diagnosed Prevalent Cases of Inflammatory Myositis in EU4 and the UK (2019-2032)
• Figure 14: Diagnosed Prevalent Cases of Inflammatory Myositis in Japan (2019-2032)
• Figure 15: Gender-specific Diagnosed Prevalent Cases of Inflammatory Myositis in Japan (2019-2032)
• Figure 16: Age-specific Diagnosed Prevalent Cases of Inflammatory Myositis in Japan (2019-2032)
• Figure 17: Total Market Size of Inflammatory Myositis in the 7MM, in USD million (2019-2032)
• Figure 18: Total Market Size of Inflammatory Myositis by Therapies in the 7MM, in USD million (2019-2032)
• Figure 19: Market Size of Inflammatory Myositis in the United States, in USD million (2019-2032)
• Figure 20: Market Size of Inflammatory Myositis By Therapies in the US, in USD million (2019-2032)
• Figure 21: Market Size of Inflammatory Myositis in EU4 and the UK, in USD million (2019-2032)
• Figure 22: Market Size of Inflammatory Myositis by Therapies in EU4 and the UK, in USD million (2019-2032)
• Figure 23: Market Size of Inflammatory Myositis in Japan, in USD million (2019-2032)
• Figure 24: Market Size of Inflammatory Myositis by Therapies in Japan, in USD million (2019-2032)
• Figure 25: Health Technology Assessment
• Figure 26: Reimbursement Process in Germany
• Figure 27: Reimbursement Process in France
• Figure 28: Reimbursement Process in Spain
• Figure 29: Reimbursement Process in the United Kingdom
• Figure 30: Reimbursement Process in Japan

Key Highlights::

• In 2022, the market size of inflammatory myositis was highest in the US among the 7MM, accounting for approximately USD 293 million which is further expected to increase by 2032.
• Some of the products that are likely to hit the market during our study period 2019-2032 include Efgartigimod alfa, Ravulizumab, Brepocitinib, PF-06823859, and Hizentra.

DelveInsight's "Inflammatory myositis (IM)- Market Insights, Epidemiology and Market Forecast- 2032" report delivers an in-depth understanding of the Inflammatory myositis, historical and forecasted epidemiology as well as the Inflammatory myositis market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Inflammatory myositis (IM) market report provides current treatment practices, emerging drug, market size and market share of the individual therapies, current and forecasted 7MM from 2019 to 2032. The report also covers current inflammatory myositis treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2019-2032.

Inflammatory myositis (IM) Disease Understanding and Treatment Algorithm

The term myositis refers to a condition where there is inflammation of muscle. In practice, myositis tends to be associated with the idiopathic inflammatory myopathies (IMM): polymyositis (PM), dermatomyositis (DM), juvenile dermatomyositis, overlap myositis, and inclusion body myositis (IBM). In contrast, myopathy refers to any abnormal condition or disease of muscle and, by definition, includes myositis.

Myositis is a rare condition that can affect multiple organs apart from muscles and often leads to severe impairment of the quality of life. According to the American College of Rheumatology, inflammatory myopathies are muscle diseases caused by inflammation. Myopathy is a general term used to describe several conditions affecting the muscles. They are autoimmune diseases where the body's immune system mistakenly attacks its muscles. The most common inflammatory myopathies are dermatomyositis and polymyositis.

Inflammatory myositis (IM) Diagnosis

Diagnosing myopathies involves a laboratory evaluation, imaging studies, multidisciplinary consultations, histologic examination, and potentially genetic studies. To properly diagnose the patient with muscle weakness, testing should include a thorough history and physical examination, routine laboratory tests (complete blood count, complete metabolic panel, muscle enzymes, thyroid-stimulating hormone, and other targeted studies as necessary), autoimmune serologies, imaging studies, neurologic evaluation, EMG, nerve conduction velocities and muscle biopsy. The history and physical examination allow the patient to describe the onset of the disease.

Further details related to country-based variations are provided in the report

Inflammatory myositis (IM) Treatment

The treatment landscape for inflammatory myositis (including dermatomyositis, polymyositis, and inclusion body myositis) involves a combination of medications and supportive therapies. The specific treatment approach may vary depending on the individual's symptoms, disease severity, and response to previous treatments. Some common treatment options are:

Corticosteroids: High-dose corticosteroids, such as prednisone, are often the first-line treatment for inflammatory myositis. They help reduce inflammation and suppress the immune response. The dosage is typically gradually reduced to find the lowest effective dose.

Immunosuppressants: Immunosuppressant medications may be added if corticosteroids are insufficient or long-term corticosteroid use is not desirable. Examples include methotrexate, azathioprine, mycophenolate mofetil, and cyclosporine. These drugs work by suppressing the immune system and reducing inflammation.

Biologic agents: In some cases, biologic agents may be used for more severe or refractory cases of inflammatory myositis. Rituximab, for example, targets specific immune cells involved in the disease process. Other biologics, such as tocilizumab or abatacept, may also be considered in certain cases.

Intravenous immunoglobulin (IVIG): IVIG is a treatment option for some individuals with dermatomyositis or polymyositis who do not respond to other therapies. It involves infusions of immunoglobulin to modulate the immune system.

It is important to note that the inclusion body myositis (IBM) treatment is particularly challenging, as it is generally less responsive to immunosuppressive therapies. Currently, no specific treatment can stop or reverse the progression of IBM; however, supportive therapies, physical therapy, and management of symptoms can help improve quality of life.

A high unmet need prevails in the current therapies for treating Inflammatory myositis as current treatment approaches for inflammatory myositis typically involve immunosuppressive medications such as corticosteroids and disease-modifying antirheumatic drugs (DMARDs). However, these therapies are not always effective for all patients, and some individuals may experience inadequate response or significant side effects.

To cater to their needs, many molecules are in the pipeline to treat Inflammatory myositis patients across the 7MM. Some major products are anticipated to hit the market during 2023-2032, including Efgartigimod alfa, Ravulizumab, Brepocitinib, PF-06823859, and Hizentra.

Inflammatory myositis (IM) Epidemiology

As the market is derived using a patient-based model, the Inflammatory myositis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases of Inflammatory myositis, type-specific diagnosed prevalent cases of Inflammatory myositis, gender-specific diagnosed prevalent cases of Inflammatory myositis, and age-specific diagnosed prevalent cases of Inflammatory myositis in the 7MM covering, the United States, EU4 countries (Germany, France, Italy, and Spain), United Kingdom, and Japan from 2019 to 2032.

• There were 184,204 diagnosed prevalent cases of Inflammatory myositis estimated to have occurred in the 7MM in 2022 of which 90,064 of the accounted cases were estimated to be from the US alone and these cases are anticipated to increase during forecasted period
• The diagnosed prevalent cases were further divided into type specific cases. The type-specific diagnosed prevalent cases of Inflammatory myositis is further categorized into PM, DM, and IBM with 74,916, 82,534, and 26,754 cases respectively in the 7MM in 2022 which will further increase by 2032.
• The age specific cases of Inflammatory myositis was divided into 0-17 years, 18-44 years, 45-64 years, 65 years, and above, respectively with 6,663, 44,156 , 77,686, and 55,700 cases in the 7MM in 2022.
• The gender specific diagnosed prevalent cases is further divided into males and females with 68,910 and 115,294 cases in the 7MM in 2022 which is further projected to increase during forecasted period.

Inflammatory myositis (IM) Drug Chapters

The drug chapter segment of the inflammatory myositis report encloses a detailed analysis of Inflammatory myositis late-stage and mid-stage (Phase-III and Phase-II) pipeline drug. It also helps to understand the Inflammatory myositis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Emerging Drugs:

Efgartigimod: Argenx

Efgartigimod, an experimental antibody fragment, is specifically designed to target the neonatal Fc receptor (FcRn) and is considered a pioneering treatment option. It is currently undergoing evaluation for its potential to treat patients who suffer from inflammatory myositis, a severe autoimmune disease. These patients have confirmed levels of pathogenic immunoglobulin G (IgG) autoantibodies, and there is a significant lack of effective medical solutions for their condition.

PF-06823859, an investigational drug developed by Pfizer, is currently in Phase II developmental stages as a potential treatment for moderate-to-severe dermatomyositis and lupus. This drug candidate is categorized as a new biological entity (NBE) and is a humanized immunoglobulin-neutralizing antibody. It is administered via IV and SC injection and works by specifically targeting interferon beta 1 (IFNB1), a key cytokine involved in the pathogenesis of these diseases.

Detailed emerging therapies list will be provided in the final report.

Inflammatory myositis (IM) Market Outlook

The treatment landscape for inflammatory myositis has evolved over the years. Current treatment approaches involve a combination of immunosuppressive medications, such as corticosteroids and disease-modifying anti-rheumatic drugs (DMARDs) i.e. immunosuppressive agents, biologic agents, physical therapy, and supportive measures. However, there is still an unmet need for more effective and targeted therapies with fewer side effects. The development of novel treatments, including biologics and small molecule inhibitors, could significantly impact the market outlook by offering new options for patients.

The effectiveness and safety of intravenous immunoglobulin (IVIg) as the initial treatment for patients diagnosed with idiopathic inflammatory myopathy. First-line IVIg monotherapy demonstrated effectiveness in approximately 50% of patients with idiopathic inflammatory myopathies. In most cases, treatment response was achieved within three weeks of initiating IVIg therapy among those who responded positively. If treatment with corticosteroids, immunosuppressive agents, and IVIG fails to alleviate symptoms, IV cyclophosphamide can be considered as a fourth-line treatment. However, it is associated with potential severe side effects and is typically reserved for patients with severe refractory disease, such as profound muscle weakness, swallowing difficulties, and interstitial lung disease. Treatment plans may vary depending on the individual's specific condition, disease severity, response to treatment, and the expertise of the treating physician.

In light of the above, some developmental initiatives have been taken toward the management of IM. The condition may evolve as some interesting therapies are heading down the pipeline. This would encourage reimbursement scenarios, doctors' adoption, and patient compliance. Some companies have initiated clinical trials investigating new treatment options, including Argenx (Efgartigimod), CSL Behring (Hizentra), Pfizer (PF-06823859), Priovant Therapeutics (Beprocitinib), and Alexion Pharmaceuticals (Ravulizumab) as the potential therapies lined up for forecast in the 7MM in the DelveInsight therapeutics market model.

• The total market size of Inflammatory myositis in the 7MM is approximately USD 575 million in 2022 and is projected to increase during the forecast period (2023-2032)
• The market size in the 7MM will increase at a CAGR of about 11.7% due to increasing awareness of the disease and launch of the emerging drug
• Among EU countries, Germany and Italy accounts for the maximum market size of USD 68 and USD 46 million in 2022 while Spain occupies the bottom of the ladder in the same year with USD 21 million.
• Japan accounts for market size of USD 71 million in 2022, but these dynamics are expected to change in the forecasted years.

Inflammatory myositis (IM) Drug Uptake

This section focuses on the rate of uptake of the potential drug expected to get launched in the market during the study period 2019-2032. For example, we estimate that both drug (efgartigimod, Ravulizumab, Brepocitinib, PF-06823859, and Hizentra) will be launched in the year 2028, 2025, 2026, 2027 and 2025 in the US, respectively. The drugs are under development in the Phase II or III stage.

Further detailed analysis of emerging therapies drug uptake in the report…

Inflammatory myositis (IM) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers detailed information on collaborations, acquisition and merger, licensing, and patent details for Inflammatory myositis emerging therapies.

KOL- Views:

To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on Inflammatory myositis evolving treatment landscape, patient reliance on conventional therapies, patient's therapy switching acceptability, drug uptake along with challenges related to accessibility, include the Division of Rheumatology at the University of California in Irvine, USA; Division of Medicine, Georgetown University Medical School, USA; Department of Medical Biotechnology, Berlin, Germany; University Paris-Saclay, France; Centre for Biomedical Investigation Network, Barcelona, Spain; Graduate School of Medicine, Chiba University, Japan, and Others.

DelveInsight's analysts connected with 50+ KOLs to gather insights, however, interviews were conducted with 15+ KOLs in the 7MM. Centers such as the Department of Rheumatology, Department of Immunology, etc. were contacted. Their opinion helps to understand and validate current and emerging therapies and treatment patterns or Inflammatory myositis market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis, and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Conjoint Analysis is done to analyze multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy. In efficacy, the trial's primary and secondary outcome measures are evaluated.

Further, the safety of the drug is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Market Access and Reimbursement

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Report:

• The report covers a segment of key events, an executive summary, descriptive overview of inflammatory myositis, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosed patient, disease progression along with treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging therapies along with the elaborative profiles of late-stage and prominent therapies will have an impact on the current treatment landscape.
• A detailed review of the inflammatory myositis market; historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM Inflammatory myositis market.

Inflammatory myositis (IM) Report Insights

• Patient Population
• Therapeutic Approaches
• Pipeline Analysis
• Inflammatory myositis Market Size and Trends
• Existing and future Market Opportunity

Inflammatory myositis (IM) Report Key Strengths

• 10 Years Forecast
• 7MM Coverage
• Inflammatory myositis Epidemiology Segmentation
• Key Cross Competition
• Attribute analysis
• Drug Uptake and Key Market Forecast Assumptions

Inflammatory myositis (IM) Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT and Attribute Analysis)

Key Questions:

Market Insights:

• What was the inflammatory myositis total market size, the market size by therapies, and market share (%) distribution in 2019, and how it would all look in 2032? What are the contributing factors for this growth?
• Will the coverage of drug depend on their efficacy in inflammatory myositis?
• What will be the impact on the market with the launch of emerging drug?
• How much market will be captured by efgartigimod, ravulizumab, brepocitinib, PF-06823859, and Hizentra after its launch?
• Which drug is going to be the largest contributor to the market in 2032?
• What are the pricing variations among different geographies for approved and off-label therapies?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What are the disease risk, burdens, and unmet needs of inflammatory myositis? What will be the growth opportunities across the 7MM with respect to the patient population pertaining to inflammatory myositis?
• What is the historical and forecasted Inflammatory myositis patient pool in the United States, EU4 (Germany, France, Italy, and Spain) the United Kingdom, and Japan?
• How many patients are of PM, DM, and IBM of inflammatory myositis?
• Age specific cases of inflammatory myositis?
• What factors are affecting the increase in the diagnosis of inflammatory myositis?

Current Treatment Scenario, Marketed Drug, and Emerging Therapies:

• What are the current options for the standard of care of inflammatory myositis? What are the current treatment guidelines for the treatment of Inflammatory myositis in the US and Europe?
• How many companies are developing therapies for the treatment of inflammatory myositis?
• How many emerging therapies are in the mid-stage and late stage of development for the treatment of inflammatory myositis?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
• What are the patents of emerging therapies for inflammatory myositis?
• What will be the impact on the market after the expected patent expiry of the emerging drug?
• What is the cost burden of marketed therapies on patients?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the country-specific accessibility issues of recommended therapies? Focus on reimbursement policies.
• What are the 7MM historical and forecasted market of inflammatory myositis?

Reasons to buy:

The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Inflammatory myositis Market

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years
• To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Detailed analysis and potential of current and emerging therapies under the conjoint analysis section to provide visibility around leading emerging drug.
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs
• To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in future.
• Detailed insights on the unmet need of the existing market so that the upcoming players can strengthen their development and launch strategy.

Table of Contents

1. Key Insights

2. Report Introduction

3. Inflammatory Myositis Market Overview at a Glance

• 3.1. Market Share (%) Distribution of Inflammatory Myositis in 2019
• 3.2. Market Share (%) Distribution of Inflammatory Myositis in 2032

4. Epidemiology and Market Forecast Methodology

5. Key Events

6. Executive Summary of Inflammatory Myositis

7. Disease Background and Overview: Inflammatory Myositis

• 7.1. Introduction
• 7.2. Clinical Manifestations
• 7.3. Etiology and Risk Factors
• 7.4. Immunopathogenesis
  • 7.4.1. Pathogenesis
  • 7.4.2. Innate Immune Mechanisms of Muscle Damage in Myositis
  • 7.4.3. TLR Signaling in Skeletal Muscle
• 7.5. Comorbidity Associated With Inflammatory Myositis
• 7.6. Diagnosis
  • 7.6.1. Differential Diagnosis
  • 7.6.2. Diagnostic Guidelines
    • 7.6.2.1. The Myositis Association Diagnostic Criteria
    • 7.6.2.2. Diagnostic Criteria for Sporadic Inclusion Body Myositis by Research Group on Rare Intractable Muscle Diseases in co-operation With The Japanese Society of Neurology
    • 7.6.2.3. International Diagnostic Criteria for Inflammatory Myopathies
    • 7.6.2.4. 2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and their Major Subgroups
• 7.7. Management and Treatment
  • 7.7.1. Treatment Guidelines
    • 7.7.1.1. British Society for Rheumatology Guideline on Management of Pediatric, Adolescent, and Adult Patients With Idiopathic Inflammatory Myopathy
    • 7.7.1.2. Consensus-based Recommendations for the management of Juvenile Dermatomyositis
    • 7.7.1.3. Polymyositis and Dermatomyositis Clinical Practice Guidelines (2020 Provisional Version) by Ministry of Health, Labor, and Welfare Research Grants Policy Research Project for Intractable Diseases (Research Group on Autoimmune Diseases)
    • 7.7.1.4. Clinical Practice Guidance for Juvenile Dermatomyositis (JDM) 2018

8. Patient Journey

9. Epidemiology and Patient Population of Inflammatory Myositis

• 9.1. Key Findings
• 9.2. Assumptions and Rationale: The 7MM
  • 9.2.1. The United States
  • 9.2.2. EU4 and the UK
  • 9.2.3. Japan
• 9.3. Diagnosed Prevalent Cases of Inflammatory Myositis in the 7MM
• 9.4. The United States
  • 9.4.1. Diagnosed Prevalent Cases of Inflammatory Myositis in the US
  • 9.4.2. Type specific Diagnosed Prevalent Cases of Inflammatory Myositis in the US
  • 9.4.3. Gender-specific Diagnosed Prevalent Cases of Inflammatory Myositis in the US
  • 9.4.4. Age-specific Diagnosed Prevalent Cases of Inflammatory Myositis in the US
• 9.5. EU4 Countries and the UK
  • 9.5.1. Diagnosed Prevalent Cases of Inflammatory Myositis in EU4 and the UK
  • 9.5.2. Type specific Diagnosed Prevalent Cases of Inflammatory Myositis in EU4 and the UK
  • 9.5.3. Gender-specific Diagnosed Prevalent Cases of Inflammatory Myositis in EU4 and the UK
  • 9.5.4. Age-specific Diagnosed Prevalent Cases of Inflammatory Myositis in EU4 and the UK
• 9.6. Japan
  • 9.6.1. Diagnosed Prevalent Cases of Inflammatory Myositis in Japan
  • 9.6.2. Type specific Diagnosed Prevalent Cases of Inflammatory Myositis in Japan
  • 9.6.3. Gender-specific Diagnosed Prevalent Cases of Inflammatory Myositis in Japan
  • 9.6.4. Age-specific Diagnosed Prevalent Cases of Inflammatory Myositis in Japan

10. Marketed Drug

• 10.1. OCTAGAM 10% (intravenous immune globulin [human]): Octapharma
  • 10.1.1. Product Description
  • 10.1.2. Regulatory Milestone
  • 10.1.3. Clinical Development
  • 10.1.4. Clinical Trials Information
  • 10.1.5. Safety and Efficacy
  • 10.1.6. Product Profile

11. Emerging Therapies

• 11.1. Key Cross Competition
• 11.2. Hizentra: CSL Behring
  • 11.2.1. Product Description
  • 11.2.2. Other Development Activities
  • 11.2.3. Clinical Development
  • 11.2.4. Clinical Trials Information
  • 11.2.5. Safety and Efficacy
  • 11.2.6. Product Profile
  • 11.2.7. Analyst Views
• 11.3. PF 1801: Immunoforge Co. Ltd.
  • 11.3.1. Product Description
  • 11.3.2. Other Development Activities
  • 11.3.3. Clinical Development
  • 11.3.4. Clinical Trials Information
  • 11.3.5. Safety and Efficacy
  • 11.3.6. Product Profile
  • 11.3.7. Analysts' Views
• 11.4. Efgartigimod: Argenx
  • 11.4.1. Product description
  • 11.4.2. Other Development Activities
  • 11.4.3. Clinical Development
  • 11.4.4. Clinical Trials Information
  • 11.4.5. Safety and Efficacy
  • 11.4.6. Product Profile
  • 11.4.7. Analyst Views
• 11.5. Nipocalimab: Janssen
  • 11.5.1. Product Description
  • 11.5.2. Other Development Activities
  • 11.5.3. Clinical Development
  • 11.5.4. Clinical Trials Information
  • 11.5.5. Product Profile
• 11.6. ABC008: Abcuro, Inc.
  • 11.6.1. Product Description
  • 11.6.2. Other Development Activities
  • 11.6.3. Clinical Development
  • 11.6.4. Clinical Trial Information
  • 11.6.5. Safety and Efficacy
  • 11.6.6. Product Profile
  • 11.6.7. Analyst Views
• 11.7. Daxdilimab (HZN-7734/MEDI7734/VIB7734): Horizon Therapeutics
  • 11.7.1. Product Description
  • 11.7.2. Other Development Activities
  • 11.7.3. Clinical Development
  • 11.7.4. Clinical Trial Information
  • 11.7.5. Product Profile
• 11.8. Enpatoran (M5049): Merck KGaA
  • 11.8.1. Product Description
  • 11.8.2. Clinical Development
  • 11.8.3. Clinical Trial Information
  • 11.8.4. Product Profile
• 11.9. GLPG3667: Galapagos NV
  • 11.9.1. Product Description
  • 11.9.2. Other Development Activities
  • 11.9.3. Clinical Development
  • 11.9.4. Clinical Trial Information
  • 11.9.5. Product profile
• 11.10. Brepocitinib (PF-06700841): Priovant Therapeutics/Roivant
  • 11.10.1. Product Description
  • 11.10.2. Other Developmental Activities
  • 11.10.3. Clinical Development
  • 11.10.4. Clinical Trials Information
  • 11.10.5. Safety and Efficacy
  • 11.10.6. Product Profile
  • 11.10.7. Analysts' Views
• 11.11. ULTOMIRIS (Ravulizumab): Alexion Pharmaceuticals
  • 11.11.1. Product Description
  • 11.11.2. Other Developmental Activities
  • 11.11.3. Clinical Development
  • 11.11.4. Clinical Trials Information
  • 11.11.5. Product Profile
  • 11.11.6. Analysts' Views
• 11.12. PF-06823859 (Dazukibart): Pfizer
  • 11.12.1. Product Description
  • 11.12.2. Other Developmental Activities
  • 11.12.3. Clinical Development
  • 11.12.4. Clinical Trials Information
  • 11.12.5. Safety and Efficacy
  • 11.12.6. Product Profile
  • 11.12.7. Analysts' Views
• 11.13. Zetomipzomib (KZR-616): Kezar Life Sciences
  • 11.13.1. Product Description
  • 11.13.2. Other Developmental Activities
  • 11.13.3. Clinical Development
  • 11.13.4. Clinical Trials Information
  • 11.13.5. Safety and Efficacy
  • 11.13.6. Product Profile
  • 11.13.7. Analysts' Views

12. Inflammatory Myositis: Seven Major Market Analysis

• 12.1. Key Findings
• 12.2. Market Outlook
• 12.3. Key Market Forecast Assumptions
• 12.5. Market Size of Inflammatory Myositis in the 7MM
• 12.6. Market Size of Inflammatory Myositis by Therapies in the 7MM
• 12.7. Market Size of Inflammatory Myositis in the United States
  • 12.7.1. Total Market Size of Inflammatory Myositis
  • 12.7.2. Market Size of Inflammatory Myositis by Therapies
• 12.8. Market Size of Inflammatory Myositis in EU4 and the UK
  • 12.8.1. Total Market Size of Inflammatory Myositis
  • 12.8.2. Market Size of Inflammatory Myositis by Therapies
• 12.9. Market Size of Inflammatory Myositis in Japan
  • 12.9.1. Total Market Size of Inflammatory Myositis
  • 12.9.2. Market Size of Inflammatory Myositis by Therapies

13. Key Opinion Leaders' Views

14. SWOT Analysis

15. Unmet Needs

16. Market Access and Reimbursement

• 16.1. The United States
  • 16.1.1. Centre for Medicare and Medicaid Services (CMS)
• 16.2. In EU4 and the UK
  • 16.2.1. Germany
  • 16.2.2. France
  • 16.2.3. Italy
  • 16.2.4. Spain
  • 16.2.5. The United Kingdom
• 16.3. Japan
  • 16.3.1. MHLW

17. Appendix

• 17.1. Bibliography
• 17.2. Acronyms and Abbreviations
• 17.3. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer